TissueGene
Rockville
About TissueGene
TissueGene is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D, and TG-N for the regeneration of cartilage, bone, disc, and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $124.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: kosdaq:950160
- Website: tissuegene.com
- Phone: (301)921-6000
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tissuegene-22438 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.